"Designing Growth Strategies is in our DNA"

U.S. Sickle Cell Disease Treatment Market Size, Share & COVID-19 Impact Analysis, By Treatment Modality [Bone Marrow Transplant, Blood Transfusion, Pharmacotherapy {Hydroxyurea, Branded Products (Endari, Adakveo, Oxbryta, Zynteglo, PYRUKYND (Mitapivat), CTX001, Inclacumab, MGTA-145, Vamifeport (VIT-2763), ALXN1820, FT-4202, and GBT021601)}], By End-user (Hospitals, Specialty Clinics, and Others), and Country Forecast, 2023-2030

Last Updated: December 01, 2025 | Format: PDF | Report ID: FBI108646

 

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
    4. Market Trends
  4. Key Insights
    1. Prevalence of Sickle Cell Disease in the U.S., 2021/2022
    2. Overview of Branded Drugs Approved in the U.S.
    3. Pipeline Analysis, Key Players
    4. New Product Launches, Key Players
    5. Key Industry Developments (Mergers, Acquisitions, Partnership; etc.)
    6. Impact of COVID-19 on the Market
  5. U.S. Sickle Cell Disease Treatment Market Analysis, Insights and Forecast, 2019-2030
    1. Market Analysis, Insights and Forecast – By Treatment Modality
      1. Bone Marrow Transplant
      2. Blood Transfusion
      3. Pharmacotherapy
        1. Hydroxyurea
        2. Branded Products
          1. Endari
          2. Adakveo
          3. Oxbryta
          4. PYRUKYND (Mitapivat)
          5. Zynteglo
          6. CTX001
          7. Inclacumab
          8. Vamifeport (VIT-2763)
          9. ALXN1820
          10. MGTA-145
          11. FT-4202
          12. GBT021601
    2. Market Analysis, Insights and Forecast – By End-user
      1. Hospitals
      2. Specialty Clinics
      3. Others
  6. Competitive Analysis
    1. U.S. Market Share Analysis (2022)
    2. Company Profiles
      1. Bristol-Myers Squibb Company
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      2. Addmedica
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      3. Novartis AG
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      4. Global Blood Therapeutics, Inc. (Pfizer Inc.)
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      5. Emmaus Medical, Inc.
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      6. bluebird bio Inc.
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      7. Agios Pharmaceuticals, Inc.
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
    4. Market Trends
  4. Key Insights
    1. Prevalence of Sickle Cell Disease in the U.S., 2021/2022
    2. Overview of Branded Drugs Approved in the U.S.
    3. Pipeline Analysis, Key Players
    4. New Product Launches, Key Players
    5. Key Industry Developments (Mergers, Acquisitions, Partnership; etc.)
    6. Impact of COVID-19 on the Market
  5. U.S. Sickle Cell Disease Treatment Market Analysis, Insights and Forecast, 2019-2030
    1. Market Analysis, Insights and Forecast – By Treatment Modality
      1. Bone Marrow Transplant
      2. Blood Transfusion
      3. Pharmacotherapy
        1. Hydroxyurea
        2. Branded Products
          1. Endari
          2. Adakveo
          3. Oxbryta
          4. PYRUKYND (Mitapivat)
          5. Zynteglo
          6. CTX001
          7. Inclacumab
          8. Vamifeport (VIT-2763)
          9. ALXN1820
          10. MGTA-145
          11. FT-4202
          12. GBT021601
    2. Market Analysis, Insights and Forecast – By End-user
      1. Hospitals
      2. Specialty Clinics
      3. Others
  6. Competitive Analysis
    1. U.S. Market Share Analysis (2022)
    2. Company Profiles
      1. Bristol-Myers Squibb Company
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      2. Addmedica
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      3. Novartis AG
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      4. Global Blood Therapeutics, Inc. (Pfizer Inc.)
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      5. Emmaus Medical, Inc.
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      6. bluebird bio Inc.
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      7. Agios Pharmaceuticals, Inc.
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
Read Less

Table 01: U.S. Sickle Cell Disease Treatment Market Revenue (USD billion) Forecast, By Treatment Modality, 2019–2030

Table 02: U.S. Sickle Cell Disease Treatment Market Revenue (USD billion) Forecast, By Pharmacotherapy, 2019–2030

Table 03: U.S. Sickle Cell Disease Treatment Market Revenue (USD billion) Forecast, By Branded Products, 2019–2030

Table 04: U.S. Sickle Cell Disease Treatment Market Revenue (USD billion) Forecast, By End-user, 2019–2030

Figure 01: U.S. Sickle Cell Disease Treatment Market Revenue Breakdown (USD billion, %) by Treatment Modality, 2022 & 2030

Figure 02: U.S. Sickle Cell Disease Treatment Market Value Share (%), By Treatment Modality, 2022 & 2030

Figure 03: U.S. Sickle Cell Disease Treatment Market Value Share (%), By End-user, 2022 & 2030

Figure 04: U.S. Sickle Cell Disease Treatment Market Share (%), by Company, 2022

U.S. Sickle Cell Disease Treatment Market
  • 2019-2030
  • 2022
  • 2019-2021
  • 40
Download Free Sample

    man icon
    Mail icon
    Captcha refresh
Growth Advisory Services
    How can we help you uncover new opportunities and scale faster?
Clients
3M
Toshiba
Fresenius
Johnson
Siemens
Abbot
Allergan
American Medical Association
Becton, Dickinson and Company
Bristol-Myers Squibb Company
Henry Schein
Mckesson
Mindray
National Institutes of Health (NIH)
Nihon Kohden
Olympus
Quest Diagnostics
Sanofi
Smith & Nephew
Straumann

Related Reports